Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling.

Toxicity and emerging drug resistance are important challenges in PARP inhibitor (PARPi) treatment of ovarian cancer. Recent research has shown that evolutionary-inspired treatment algorithms which adapt treatment to the tumor's treatment response (adaptive therapy) can help to mitigate both. Here, we present a first step in developing an adaptive therapy protocol for PARPi treatment by combining mathematical modelling and wet-lab experiments to characterize the cell population dynamics under different PARPi schedules. Using data from

Déclaration de conflit d'intérêts

Competing Interests: R.M.W. reports grants and consulting fees from Merck, consulting fees from Tesaro/GSK, consulting fees from Genentech, consulting fees from Legend Biotech, grants and consulting fees from AbbVie, grants and consulting fees from Astrazeneca, consulting fees from Novacure, consulting fees, grants and stock from Ovation Diagnostics, honoraria from Clovis Oncology, consulting fees and grants from Eisai, consulting fees from Seagen, consulting fees from Shattuck Labs, consulting fees from Immunogen, and consulting fees and grants from Regeneron (all outside the submitted work). All other authors declare no competing interests.